Trials / Completed
CompletedNCT05884242
A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
Intervention Specific Appendix to PLATFORMPBNAP1001: Evaluation of The Effect of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to characterize the inflammatory response to lipopolysaccharide (LPS; molecules that contains fats and carbohydrates) in the presence of a targeted immune pathway modulator.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab | Adalimumab will be administered subcutaneously. |
| DRUG | Lipopolysaccharide (LPS) | LPS will be administered intravenously. |
Timeline
- Start date
- 2023-05-22
- Primary completion
- 2023-08-01
- Completion
- 2023-08-07
- First posted
- 2023-06-01
- Last updated
- 2025-03-30
Locations
1 site across 1 country: Belgium
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05884242. Inclusion in this directory is not an endorsement.